EZH2 inhibitor GSK-343 enhances human mononuclear cell reparative function post-myocardial infarction, thereby preventing infarct size expansion and cardiac dysfunction, by resolving H3K27 methylation and promoting inflammation resolution (Rondeaux et al., 2023). Here, EZH2 is linked to myocardial infarction.